New pneumonia vaccine candidate enters early human testing

NCT ID NCT07428759

Ongoing ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new pneumococcal vaccine called PnMAPS30plus in 121 healthy adults aged 50 to 64. Participants receive a single shot of either the new vaccine or an approved one (PCV20) and are monitored for about six months. The goal is to check safety and whether the vaccine triggers a strong immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PnMAPS30plus (investigational pneumococcal vaccine)
What this could lead to: If successful, this could lead to a new vaccine option to protect against pneumococcal disease in older adults.
What could go wrong: This is an early Phase 1 trial with only 121 participants, so it's too soon to know if the vaccine works or is safe. The study focuses on safety and immune response, not on preventing pneumonia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMONIA, BACTERIAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial pneumonia pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMONIA, BACTERIAL

Contacts and locations

Locations

GSK Investigational Site

Norwood, South Australia, 5067, Australia
GSK Investigational Site

Camberwell, Victoria, 3124, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.